ReviewFertility and sterility2022
Subclinical cardiovascular disease and polycystic ovary syndrome.
Review in Fertility and sterility, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 2 syntheses or guidelines pooled it, 63 citations in OpenAlex.
- 2023 International Evidence-Based Polycystic Ovary Syndrome Guideline Update: Insights From a Systematic Review and Meta-Analysis on Elevated Clinical Cardiovascular Disease in Polycystic Ovary Syndrome.Journal of the American Heart Association · 2024Pooled it
- Blood nesfatin-1 levels in patients with polycystic ovary syndrome: a systematic review and meta-analysis.Frontiers in endocrinology · 2023Pooled it
- Impact of mean arterial pressure on reproductive endocrine characteristics in infertile patients with polycystic ovary syndrome: a secondary analysis of a randomized clinical trial.Frontiers in endocrinology · 2025Trial
- Association Between Polycystic Ovary Syndrome and Markers of Subclinical Atherosclerosis in Premenopausal Women: A Systematic Review.Journal of clinical medicine · 2026Review
- Polyendocrine metabolic ovarian syndrome (PMOS)/polycystic ovary syndrome (PCOS): current and future trends.The Journal of clinical investigation · 2026Review
- Dingkun Pill-Mediated TGF-β1/Smad2 Pathway Effects on Granulosa Cell Proliferation and Apoptosis.Molecular biotechnology · 2026Article
- CIMT as a sensitive indicator of cardiovascular risk in PCOS: a case-control study of sortilin and sclerostin.BMC women's health · 2026Article
- Beyond the Usual Suspects: A Narrative Review of High-Yield Non-Traditional Risk Factors for Atherosclerosis.Journal of clinical medicine · 2026Review
- Development and validation of the polycystic ovary syndrome-related complaint severity scale.Revista da Associacao Medica Brasileira (1992) · 2026Article
- Polycystic Ovary Syndrome Revisited: Novel Insights and Updates.International journal of medical sciences · 2026Review
- Unraveling the Complexity of Polycystic Ovary Syndrome: Biomarkers for Diagnosis, Prognosis, and Treatment.Current pharmaceutical design · 2026Review
- Cardiovascular Dysfunction in Polycystic Ovary Syndrome: Mitochondrial and Inflammatory Mechanisms.BioMed research international · 2026Review
- BMI-stratified phenotypes of polycystic ovary syndrome: advances in gut microbiota research and personalized management strategies.Frontiers in endocrinology · 2026Review
- Recent advances in reprogramming lactate metabolism in polycystic ovary syndrome.Journal of ovarian research · 2025Review
- Evaluation of subclinical atherosclerosis in women with polycystic ovary syndrome based on ultra-high-frequency ultrasound and vector flow imaging.Quantitative imaging in medicine and surgery · 2025Article
- Cardiovascular contributions to dementia: Examining sex differences and female-specific factors.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Review
- Association of polycystic ovary syndrome with endothelial health, cardiovascular risk, and cellular aging.Fertility and sterility · 2025Article
- Polycystic ovary syndrome as a metabolic disease.Nature reviews. Endocrinology · 2025Review
- Effect of Junk Food on Hormonal and Metabolic Manifestations in Polycystic Ovarian Syndrome Phenotypes: A Case-Control Study of Kashmiri Population.Indian journal of clinical biochemistry : IJCB · 2025Article
- The Molecular Basis of Polycystic Ovary Syndrome and Its Cardiometabolic Correlates: Exploring the Intersection and Its Clinical Implications-A Narrative Review.Biomedicines · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Polycystic ovary syndrome (PCOS) impacts approximately 6%-10% of women worldwide, with hallmark features of hyperandrogenism, irregular menses, infertility, and polycystic appearing ovaries on ultrasound. In addition, PCOS is associated with several endocrine and metabolic disorders, including obesity, insulin resistance and diabetes mellitus, hypertension, dyslipidemia and metabolic syndrome, which all increase the risk for subclinical cardiovascular disease (CVD), the presence of altered vascular endothelium without overt CVD. In this review, we summarize the most recent literature regarding subclinical CVD in women with PCOS, including markers such as flow-mediated dilation, arterial stiffness, coronary artery calcium scores, carotid intima-media thickness and visceral and epicardial fat.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.